(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 5. Induction of human p16 promoter activity by ligand-activated PPAR
. (A) 2BS and WI-38 cells were transfected with expression plasmids pcDNA3.1 (vector) or pcDNA-PPAR
(PPAR
) as indicated, together with wild-type p16-Luc (p16 WT) or mutant p16-Luc (p16 mutant). (B) 2BS cells were transfected with expression plasmids pSilencer 2.1-U6 neo (RNAi vector) or pSilencer-PPAR
(siPPAR
) as indicated, together with wild-type p16-Luc (p16 WT). Cells were subsequently treated with 20 µM troglitazone, 10 µM pioglitazone or 10 µM GW9662. Luciferase activities were then measured 24 hours after treatment. Values are the mean ± s.d. of triplicate points from a representative experiment (n=3), which was repeated three times with similar results. *P
0.05.